DOI:
10.1055/s-00000045
Der Nuklearmediziner
LinksClose Window
References
Sartor AO, Morris MJ, Krause BJ. et al.
VISION: An international, prospective, multicenter, randomized phase 3 study of 177-Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol.
2019
37. (suppl; TPS5099)
Access:
We do not assume any responsibility for the contents of the web pages of other providers.